The Senores Pharmaceuticals IPO is set to open on December 20, 2024, and will close on December 24, 2024. The IPO has a face value of ₹10 per share, with a price band ranging from ₹372 to ₹391 per share. Investors can bid in lots of 38 shares. The total issue size is 1,48,87,723 shares, aggregating up to ₹582.11 crore, which includes a fresh issue of 1,27,87,723 shares worth ₹500 crore and an offer for sale of 21,00,000 shares amounting to ₹82.11 crore. The IPO follows a book-built issue format and will be listed on both BSE and NSE.
Before the issue, the company's shareholding stands at 3,32,65,865 shares, which will increase to 4,60,53,588 shares post-issue. The tentative timeline includes the basis of allotment on December 26, 2024, the initiation of refunds and credit of shares to Demat accounts on December 27, 2024, and the listing date on December 30, 2024.
Retail investors can apply for a minimum of 38 shares at ₹14,858, while the maximum application for retail investors is 494 shares, amounting to ₹1,93,154.
Incorporated in December 2017, Senores Pharmaceuticals Limited develops and manufactures a wide range of pharmaceutical products, primarily targeting regulated markets such as the US, Canada, and the UK. The company also extends its services to emerging markets worldwide.
Product Portfolio:
The company offers a variety of medicines, including Amphetamine Sulfate Tablets, Hydroxychloroquine Sulfate Tablets, Ketoconazole Tablets, Mexiletine Hydrochloride Capsules, Ketorolac Tromethamine Tablets, Morphine Sulfate Tablets, and Ivermectin Tablets. These products cater to various therapeutic areas, including antibiotics, antifungals, and critical care.
Key Milestones (as of September 30, 2024):
IPO stands for "Initial Public Offering." It's the process through which a privately-held company becomes publicly traded by offering its shares to the general public and listing them on a stock exchange for trading. This allows the company to raise capital from investors and grants individuals and institutions the opportunity to invest in and own a portion of the company.
The life cycle of an IPO, or Initial Public Offering, begins with a company's decision to go public. It involves hiring underwriters, registering with regulatory authorities, determining the IPO price, marketing to investors, and the subscription period where investors place orders for shares. After allocation and listing, shares become publicly tradable, and the company enters the secondary market. Ongoing reporting and corporate governance are crucial as the company continues to operate as a publicly-traded entity. The IPO aims to raise capital for growth and provides investors with opportunities to trade shares in the company.
An IPO (Initial Public Offering) is when a private company goes public by selling shares to the public. Investors buy these shares, giving them ownership in the company. It's a way for companies to raise capital and expand. The process involves underwriters, regulatory filings, setting the IPO price, and marketing to investors. After the IPO, shares can be traded on a stock exchange. IPOs offer opportunities and risks, so investors should research and consider carefully.
"Upcoming IPOs" refers to initial public offerings that have been announced by private companies but have not yet occurred. These are companies that plan to go public in the near future by issuing shares to the public and listing them on a stock exchange. Investors often keep an eye on upcoming IPOs as they represent opportunities to invest in companies at their early stages of public trading, potentially capturing growth potential. These offerings are typically accompanied by significant media and investor attention as they approach their launch dates.